Mobile

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients with Type 2 Diabetes and also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients wit...

Mise à jour : Il y a 4 ans
Référence : EUCTR2014-003511-11

A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients with Type 2 Diabetes and also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients with Different Degrees of PEI

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of Part A of the trial is to describe the distribution of plasma triglycerides in patients with Type 2 Diabetes Mellitus by degree of pancreatic exocrine insufficiency (Normal: faecal elastase-1 concentration [FEC] ≥200 μg/g; Intermediate: FEC ≥100 μg/g to <200 μg/g; and Low: FEC <100 μg/g). The primary objective of Part B of the trial is to evaluate and compare the plasma exposure of docosahexaenoic acid and eicosapentaenoic acid from EPANOVA® and OMACOR®, respectively, in patients with Type 2 Diabetes Mellitus with different levels of FEC.

Critère d'inclusion

  • Type 2 Diabetes

Liens